SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
复制标题
DOI：
10.1101/2021.01.18.427166
复制
发表时间：
2021-03-02
期刊：
影响因子：
82.9
通讯作者：
Moore, Penny L.
中科院分区：
文献类型：
--
作者：
Wibmer, Constantinos Kurt;Ayres, Frances;Moore, Penny L.
在南非首次发现的B.1.351变体中存在的SARS-CoV-2刺突蛋白的置换，当在假病毒中表达时，介导逃避临床开发中的单克隆抗体和先前感染SARS-CoV-2的个体的血浆的中和，但不能阻止恢复期血浆与含有B.1.351谱系取代的重组刺突蛋白的结合。SARS-CoV-2 501Y.V2（B.1.351）是引起COVID-19的新型冠状病毒谱系，在刺突蛋白的两个免疫显性结构域中含有取代。在这里，我们表明，假病毒表达501Y.V2刺突蛋白完全逃脱三类治疗相关的抗体。这种假病毒还表现出从恢复期血浆的中和中大量至完全逃逸，但不结合。这些数据突出了抗原性不同的变异体再感染的前景，并预示了基于加标疫苗的效力降低。
Substitutions in SARS-CoV-2 spike protein present in the B.1.351 variant first detected in South Africa, when expressed in pseudoviruses, mediate escape from neutralization by monoclonal antibodies under clinical development and by plasma from individuals previously infected with SARS-CoV-2, but do not prevent binding of convalescent plasma to recombinant spike protein containing B.1.351 lineage substitutions.SARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein. Here, we show that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies. This pseudovirus also exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and foreshadows reduced efficacy of spike-based vaccines.